From WikiProjectMed
Jump to navigation Jump to search
Monoclonal antibody
TypeFab fragment
TargetTicagrelor, AR-C124910XX (the active metabolite)[1]
Clinical data
Other namesPB2452, MEDI2452
Routes of
Intravenous infusion
ATC code
  • None
Legal status
Legal status
  • Investigational
CAS Number
PubChem SID
Chemical and physical data
Molar mass47440.93 g·mol−1

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3][4] It is not commercially available.

See also


  1. ^ "Specialist Pharmacy Service: Bentracimab". National Health Service. 10 January 2021.
  2. ^ "EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor". Cardiovascular News. 2021-01-29.
  3. ^ Clinical trial number NCT04286438 for "A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)" at
  4. ^ Makhdoum A, Dhingra NK, Kirubaharan A, Eikelboom R, Luc J, Dagher O, et al. (August 2021). "Ticagrelor use and practice patterns among Canadian cardiac surgeons". Journal of Cardiac Surgery. 36 (8): 2793–2801. doi:10.1111/jocs.15636. PMID 34028081.